Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug duo aims to shrink head and neck tumors in first-line treatment

NCT ID NCT06769698

Recruiting now Disease control Sponsor: Regeneron Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jan 08, 2026 · Last updated May 12, 2026 · Updated 17 times

Summary

This study tests whether adding an experimental drug (fianlimab) to a standard immunotherapy (cemiplimab) works better than the standard drug alone for people with head and neck cancer that has come back or spread. About 120 adults whose tumors have a specific protein (PD-L1) will receive either the combination or cemiplimab plus a placebo. The main goal is to see if the combination leads to more tumor shrinkage.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Emory University School of Medicine

    RECRUITING

    Atlanta, Georgia, 30308, United States

  • Inova Schar Cancer Institute

    RECRUITING

    Fairfax, Virginia, 22031, United States

  • Joe Arrington Cancer Research & Treatment Center

    RECRUITING

    Lubbock, Texas, 79410, United States

  • Norton Cancer Institute

    RECRUITING

    Louisville, Kentucky, 40202, United States

  • Ohio State University

    RECRUITING

    Columbus, Ohio, 43210, United States

  • Oncology Hematology West P.C. dba Nebraska Cancer Specialists

    RECRUITING

    Omaha, Nebraska, 68130, United States

  • Orlando Health

    RECRUITING

    Orlando, Florida, 32806, United States

  • Peter MacCallum Cancer Centre (PMCC)

    RECRUITING

    Melbourne, Victoria, 3050, Australia

  • St. Elizabeth Healthcare

    RECRUITING

    Edgewood, Kentucky, 41017, United States

  • Vanderbilt-Ingram Cancer Center

    RECRUITING

    Nashville, Tennessee, 37232, United States

Conditions

Explore the condition pages connected to this study.

HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC